Home › Mutual Funds › Nippon Mutual Fund › Nippon India Pharma Fund - Growth
Latest NAV & returns of NIPPON INDIA PRIVATE LTD.

Nippon India Pharma Fund - Growth

Add To Compare

previously known as Reliance Pharma Gr until

518.219 (1.900%)
NAV on August 13, 2025
Category Equity:
Sector - Healthcare
Total Assets 8,569 cr
Turnover Ratio 14.27%
Expense Ratio 1.80%
Exit Load 1.00%if redeemed within
1 Months0.00%if redeemed after 1 Months
Returns
  • 1M: 0.48%
  • 1Y: 3.90%
  • 3M: 5.49%
  • 3Y: 22.99%
  • 6M: 9.09%
  • 5Y: 18.89%
Min Investment 5,000
ADDITIONAL INFO
Fund Manager Sailesh Raj Bhan (Since over 20 years) Kinjal Desai (Since about 7 years)
ISIN INF204K01968
Fund Family Nippon
P/E Ratio 37.82
P/B Ratio 6.01
Launch Date June 05, 2004
Benchmark BSE Healthcare TR INR
ASSET ALLOCATION
CREDIT QUALITY (%)
AAA -
AA -
A -
BBB -
BB -
B -
Below B -
Unrated -
RISK MEASURES (3 yrs)
vs BSE Healthcare TR INR

Alpha 0.10
Beta 0.90
R-Squared 94.60
Info Ratio -0.51
Tracking Err 3.74
Sortino 2.081
Sharpe 1.139
Std Dev 14.615
Risk -
INVESTMENT OBJECTIVE

The primary investment objective of the scheme is to seek to generate consistent returns by investing in equity and equity related or fixed income securities of Pharma and other associated companies.

View Factsheet
-
Best Sector Healthcare Funds
NAME LATEST
NAV		 RETURNS
1y     		FUND
ASSETS		 Expense
RATIO		 RISK
Sbi
SBI Healthcare Opportunities Fund Direct Growth
490.078 11.51% 4,027 cr 0.89% -


Other plans of Nippon India Pharma

Data Partner
Click here to visit AMC website and
read all scheme related documents Nippon Fund